Search results
Showing 676 to 690 of 734 results for diabet*
This evidence summary has been updated and replaced by NICE guideline NG28.
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued Reference number: GID-HST10038
In development Reference number: GID-TAG386 Expected publication date: TBC
In development Reference number: GID-TA11352 Expected publication date: TBC
In development Reference number: GID-TA11645 Expected publication date: TBC
In development Reference number: GID-MT538 Expected publication date: TBC
This advice has been updated and replaced by NICE Healthtech guidance 615.
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)
We have moved Medical technologies guidance 22 to become HealthTech guidance 362. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Neuropad for detecting preclinical diabetic peripheral neuropathy (MTG38)
We have moved Medical technologies guidance 38 to become HealthTech guidance 486. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Medical technologies guidance 66 to become HealthTech guidance 615. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Digital technologies for multidisciplinary weight management
In development Reference number: GID-HTE10077 Expected publication date: TBC
UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)
We have moved Medical technologies guidance 42 to become HealthTech guidance 502. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Digital technologies to support smoking cessation in secondary care patients: early value assessment
In development Reference number: GID-HTE10061 Expected publication date: TBC
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.
This guidance has been replaced by NICE guideline NG17.